Mortality of patients with parkinson's disease treated with levodopa
✍ Scribed by R. J. Marttila; U. K. Rinne; T. Siirtola; V. Sonninen
- Publisher
- Springer
- Year
- 1977
- Tongue
- English
- Weight
- 372 KB
- Volume
- 216
- Category
- Article
- ISSN
- 0340-5354
No coin nor oath required. For personal study only.
✦ Synopsis
The effect of levodopa on the mortality of patients with Parkinson's disease was investigated in 349 patients treated with levodopa or levodopa combined with decarboxylase inhibitor during 1969-1975 inclusive. During the study period, 61 patients died. The expected mortality was 32.99 resulting in a ratio of actual to expected deaths of 1.85. The excess mortality was accounted for by patients with a severe disease at entry and especially, by the less favorable effect of levodopa treatment than in the living patients. In comparison with the prelevodopa era, the reduction of mortality and the increase of life expectancy of patients with Parkinson's disease during levodopa treatment possibly reflect the decrease of the early mortality due to Parkinson's disease.
📜 SIMILAR VOLUMES
## Abstract Homocysteine, cysteine, and cysteinyl‐glycine are all metabolically interrelated. Levodopa/decarboxylase inhibitor (LD/DCI) administration increases total homocysteine (tHcy) plasma levels. Objectives were to investigate associations between LD/DCI intake, concentrations of tHcy, cystei
## Abstract Dementia is a frequent non‐motor feature of Parkinson's disease (PD). Elevated plasma homocysteine (Hcy) levels have been associated with both cognitive impairment and dementia. Increased Hcy levels have been observed in levodopa‐treated patients with PD. The objective of our study was
## Abstract Subthalamic nucleus (STN) stimulation improves motor disability and quality of life in patients with advanced Parkinson's disease (PD). Short‐term mortality is low, but little is known about long‐term mortality. We assessed mortality and causes of death in 171 consecutive PD patients tr